Navigation Links
Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
Date:3/6/2008

Study Seeks Treatment to Address Skin Hardening Affects of the Devastating Disease

CHICAGO, March 6 /PRNewswire-USNewswire/ -- Physicians at Northwestern Memorial Hospital are studying the effects of an anti-cancer drug to treat patients with scleroderma, a rare, incurable autoimmune rheumatic disease that leads to hardening and tightening of the skin and connective tissues. Scleroderma affects an estimated 300,000 people in the United States and can often attack the lungs, heart, kidneys and intestinal tract, and sometimes lead to death.

The study is the first of its kind to examine if Gleevec, a cancer drug commonly used to treat leukemia, will treat the skin thickness in scleroderma patients by blocking the pathway that causes fibrosis. Patients enrolled in the clinical trial will receive daily oral doses of Gleevec for six months and will be evaluated initially on a weekly basis at Northwestern Memorial, one of only three centers nationwide participating in the study. Others include Johns Hopkins and Boston University Medical Center.

John Varga, MD, rheumatologist at Northwestern Memorial, John and Nancy Hughes Distinguished Professor in Rheumatology at Northwestern University's Feinberg School of Medicine and principal investigator of the study, said this could be a big step forward for people diagnosed with scleroderma. "Based on recent research performed by investigators at the Feinberg School, Gleevec shows potential efficacy in reducing the abnormal skin changes associated with scleroderma."

The exact cause of Scleroderma, a chronic disease most commonly found in women between the ages of 30 and 40, remains unknown. Through continued research, Northwestern Memorial physicians hope to identify treatments to target the disease and improve the quality of life for patients living with Scleroderma.

"We hope that the use of Gleevec for a sustained period of time will decrease the symptoms of skin hardening, and potentially slow the progression of this devastating disease," adds Dr. Varga.

For more information on the scleroderma Gleevec study at Northwestern, contact Julie Johnson, project coordinator, at (312) 503-2338.

About Northwestern Memorial Hospital

Northwestern Memorial Hospital is one of the country's premier academic medical centers and is the primary teaching hospital of the Northwestern University Feinberg School of Medicine. Northwestern Memorial and its Prentice Women's Hospital and Stone Institute of Psychiatry have 897 beds along with 1,424 affiliated physicians and 6,464 employees. Northwestern Memorial is recognized for providing state-of-the-art patient care and exemplary clinical and surgical advancements in the areas of cardiothoracic and vascular care, gastroenterology, neurology and neurosurgery, oncology, organ and bone marrow transplantation, and women's health. Northwestern Memorial received the prestigious 2005 National Quality Health Care Award and is listed in eight specialties in U.S. News & World Report's 2007 rankings for "America's Best Hospitals." For seven years running, Northwestern Memorial has been rated among the nation's "100 Best Companies for Working Mothers" by Working Mother magazine and has been chosen by Chicagoans for more than a decade as their "most preferred hospital" according to the National Research Corporation's annual survey. Northwestern Memorial carries the Magnet status designation in nursing, the highest recognition possible for patient care and nursing excellence.


'/>"/>
SOURCE Northwestern Memorial Hospital
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
2. Northwestern Memorial Transplant Program Initiates New Study
3. Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
4. Study Finds Starion Instruments Tissue Welding Technology Safe and Effective in Parotidectomy Procedures
5. Thomson Healthcare Cancer Profiler Used in Study
6. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
7. Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone)
8. CMC, Moffitt Partner to Study Cancer
9. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
10. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
11. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):